Keywords
Atypical hemolytic uremic syndrome
COVID-19
microangiopathic anemia
hemolytic anemia
acute respiratory distress syndrome
COVID-19
microangiopathic anemia
hemolytic anemia
acute respiratory distress syndrome
Categories
How to Cite
1.
Roa Alonso D. Atypical hemolytc uremic syndrome secondary to SARS – CoV – 2 infection. A case report. Rev Arg de Ter Int. [Internet]. 2022 Apr. 25 [cited 2024 Jul. 3];39. Available from: https://revista.sati.org.ar/index.php/MI/article/view/814
Abstract
Atypical hemolytic uremic syndrome (aHUS) is a rare entity in the intensive care unit, however, with a characteristic diagnostic triad and a specific treatment that can improve the morbidity and mortality associated with this syndrome.
Below we present the case of a 72-year-old male patient who was admitted to the intensive care unit with diagnosis of SARS-CoV-2 pneumonia, who developed aHUS secondary to this infection throughout his admission. Eculizumab could not be administered due to the sudden evolution towards multiorgan dysfunction syndrome and death.
References
1. Mokhtari T, Hassani F, Ghaffari N, Ebrahimi B, Yarahmadi A, Hassanzadeh G. COVID-19 and multiorgan failure: A narrative review on potential mechanisms. J Mol Histol. 2020 Dec;51(6):613-628. doi: 10.1007/s10735-020-09915-3. Epub 2020 Oct 4. PMID: 33011887; PMCID: PMC7533045.
2. Cheng Y, Luo R, XuW, KunW, Nanhui Z,Meng Z, ZhixiangW, Lei D, JunhuaL,Rui Z, YingY,ShuwangG,Gang X:Theincidence, risk factors, and prognosis of acute kidney injury in adult patients with COVID-19. Clin J Am Soc Nephrol 2020; 15: 1394–1402.
3. Chan L, Chaudhary K, Saha A, et al. Acute Kidney Injury in Hospitalized Patients with COVID-19 JASN 31: ccc–ccc, 2020. doi: org/10.1681/ASN.2020050615.
4. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020 Jul;8(7):738-742. doi: 10.1016/S2213-2600(20)30229-0. Epub 2020 May 14. PMID: 32416769; PMCID: PMC7255232.
5. Claudio Ronco, Dep. Nephrology Dialysis & Transplantation. San Bortolo Hospital. Vicenza, Italy. Insuficiencia Renal Aguda en la Infección por Coronavirus Sar-Cov2 (COVID-19). Ángel LM de Francisco, Hospital Universitario Valdecilla. Santander, Spain.
6. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014 Aug 14;371(7):654-66. doi: 10.1056/NEJMra1312353. PMID: 25119611.
7. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-87.
8. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, el al. An international consensus approach to the management of atypical hemolytic uremic síndrome in the children. Pediatr Nephrol. 2016;31:15-39.
9. Yu J, Yuan X, Chen H et al. Direct activation of the alternative complement patway by SARS-CoV-2 spike proteins is blocked by factor D inhinition. Blood. 2020;136:2080-2089.
10. Ficha técnica del Centro de de Información de Medicamentos de la AEMPS.-CIMA. Madrid, España: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS).
10. Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019 Nov;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3. Epub 2018 Nov 6. Erratum in: Pediatr Nephrol. 2019 Jan 15;: PMID: 30402748; PMCID: PMC6794245.
2. Cheng Y, Luo R, XuW, KunW, Nanhui Z,Meng Z, ZhixiangW, Lei D, JunhuaL,Rui Z, YingY,ShuwangG,Gang X:Theincidence, risk factors, and prognosis of acute kidney injury in adult patients with COVID-19. Clin J Am Soc Nephrol 2020; 15: 1394–1402.
3. Chan L, Chaudhary K, Saha A, et al. Acute Kidney Injury in Hospitalized Patients with COVID-19 JASN 31: ccc–ccc, 2020. doi: org/10.1681/ASN.2020050615.
4. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020 Jul;8(7):738-742. doi: 10.1016/S2213-2600(20)30229-0. Epub 2020 May 14. PMID: 32416769; PMCID: PMC7255232.
5. Claudio Ronco, Dep. Nephrology Dialysis & Transplantation. San Bortolo Hospital. Vicenza, Italy. Insuficiencia Renal Aguda en la Infección por Coronavirus Sar-Cov2 (COVID-19). Ángel LM de Francisco, Hospital Universitario Valdecilla. Santander, Spain.
6. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014 Aug 14;371(7):654-66. doi: 10.1056/NEJMra1312353. PMID: 25119611.
7. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676-87.
8. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, el al. An international consensus approach to the management of atypical hemolytic uremic síndrome in the children. Pediatr Nephrol. 2016;31:15-39.
9. Yu J, Yuan X, Chen H et al. Direct activation of the alternative complement patway by SARS-CoV-2 spike proteins is blocked by factor D inhinition. Blood. 2020;136:2080-2089.
10. Ficha técnica del Centro de de Información de Medicamentos de la AEMPS.-CIMA. Madrid, España: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS).
10. Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019 Nov;34(11):2261-2277. doi: 10.1007/s00467-018-4091-3. Epub 2018 Nov 6. Erratum in: Pediatr Nephrol. 2019 Jan 15;: PMID: 30402748; PMCID: PMC6794245.
The magazine does not retain the reproduction rights (copyright) so the authors can republish their works with the sole mention of the original publication source.